Join leading global experts as they discuss the latest research and treatment advancements in CLL from the ASH 2024 Annual Meeting. Moderated by Dr. John Seymour, this peer exchange features in-depth insights from top clinicians across Europe.
January 6th 2025
Dr Niemann provides an overview of the evolving treatment landscape of CLL.
January 8th 2025
A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.
January 15th 2025
A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.
January 24th 2025
Panelists discuss, role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.
Panelists discuss, which patients are favored for the Venetoclax-Obinutuzumab treatment approach.
January 27th 2025
Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.
Panelists discuss the role of ven-ibr in patient populations.
February 3rd 2025
Panelists review recent ESMO guideline updates for the frontline management of patients with CLL and a TP53 or del(17p) mutation.
Panelists discuss the ongoing trials evaluating other BCL2i/BTKi combination approaches.
February 10th 2025
Panelists review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy, managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy and defining early versus late relapse.
Panelists comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data.
February 17th 2025
Panelists discuss the role of non-covalent BTKis in this setting and available supporting data (high level).
Panelists comment on the increasing preference for fixed-duration therapy over treatment until progression, as reflected in recent guideline updates.